Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578331 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Olopatadine Nasal Spray
A Phase 3 study of Perennial Allergic Rhinitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 890
- Enrollment target
- 1
- Study location
NCT00578331: Completed Phase 3 study of Perennial Allergic Rhinitis, sponsored by Alcon Research.
NCT00578331 is a Phase 3 study of Perennial Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 890 participants, above the 388-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (129% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578331, a Phase 3 study of Perennial Allergic Rhinitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 890 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
Primary Outcome
Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief.
Conditions Studied
Interventions
- DRUG Placebo Nasal Spray
- DRUG Olopatadine 0.6% nasal spray
Study Locations (1)
Texas
- Waco - Waco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00578331 record still lists
NCT00578331 is an interventional study that assigns participants to a tested intervention. The registered 890 participants enrollment target is mid-sized for trials with a published cap, above the 388-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (129% higher).
The record links to 1 condition, with Perennial Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Nasal Spray is the first listed.
NCT00578331 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00578331 about?
NCT00578331 is a clinical study titled "Safety Study of Olopatadine Nasal Spray". The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
What is the current status of trial NCT00578331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 890 participants. The study started on 2006-12. Estimated completion is 2008-01.
What conditions does trial NCT00578331 study?
This clinical trial studies the following conditions: Perennial Allergic Rhinitis.
What interventions are being tested in trial NCT00578331?
The interventions under investigation include: Placebo Nasal Spray (DRUG), Olopatadine 0.6% nasal spray (DRUG).
Who is sponsoring clinical trial NCT00578331?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578331 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Perennial Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 3
-
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
COMPLETED · Phase 3
-
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 4
-
Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia